Abstract:Background: Alzheimer's disease (AD), is a progressive neurodegenerative disease that is characterized by cognitive loss. Most researchers believe that aggregation and accumulation of β-amyloid peptides (Aβ) in brain cells are the central pathological hallmark of this disease. Methods: Based on the amyloid hypothesis, a 10 amino acids β-sheet breaker peptide HPYD (His-Lys-Gln-Leu-Pro-Phe-Tyr-Glu-Glu-Asp) was designed according to the structure and sequence of the previous designed peptide H102. Accelerated stability test, thioflavine T (ThT) fluorescence spectral analysis and transmission electron microscopy (TEM) imaging were performed to detect the stability and inhibitory effects on the aggregation of Aβ1-42 by H102 and HPYD. FITC-labeled HPYD was first tested to determine whether it could be transferred along the olfactory pathway to the brain after nasal administration to mice. Subsequently, the Morris Water Maze (MWM) test for behavioral analysis was used to investigate the learning and memory ability of APP/PS1 transgenic mice by HPYD. Immunohistochemistry and western blot analysis was performed to determine the role of HPYD on Aβ and APP protein levels. In addition, microarray analysis was used to evaluate the effect of HPYD on gene expression in AD mouse models. Results: Our in vitro results demonstrated that HPYD had enhanced stability and inhibitory effects on Aβ1-42 aggregation compared to H102. HPYD could be delivered into the brain through nasal administration and improved the learning and memory ability in APP/PS1 transgenic mouse models by reducing Aβ and APP protein levels. In addition, microarray analyses suggested that several genes related to the inflammatory pathway, AD and gluco-lipid metabolism were dysregulated and could be restored to almost normal levels after HPYD administration to mice. Conclusions: Our results demonstrated that HPYD could be a potential therapeutic drug candidate for the treatment of AD.

A Β-Sheet-targeted Theranostic Agent for Diagnosing and Preventing Aggregation of Pathogenic Peptides in Alzheimer’s Disease

β-Sheet Breaker Peptide-HPYD for the Treatment of Alzheimer's Disease: Primary Studies on Behavioral Test and Transcriptional Profiling

[In Vitro Early Detection of Amyloid Plaques in Alzheimer's Disease by Pittsburgh Compound B-modified Magnetic Nanoparticles].

Brain Targeting and Aβ Binding Bifunctional Nanoparticles Inhibit Amyloid Protein Aggregation in APP/PS1 Transgenic Mice.

A Conformationally-Locked P-Hydroxybenzylidene Imidazolinone Derivative for Detecting Aβ42 Aggregation

An AIE-active Theranostic Probe for Light-Up Detection of Aβ Aggregates and Protection of Neuronal Cells.

Functional bioprobe for responsive imaging and inhibition of amyloid-β oligomer based on curcuminoid scaffold

Advances in targeted tracking and detection of soluble amyloid-β aggregates as a biomarker of Alzheimer's disease

Self-Assembly Molecular Chaperone to Concurrently Inhibit the Production and Aggregation of Amyloid Β Peptide Associated with Alzheimer’s Disease

An Activatable Small-Molecule Fluorogenic Probe for Detection and Quantification of Beta-Amyloid Aggregates

Inhibition of Amyloid Β Aggregation and Cytotoxicity by Berbamine Hydrochloride.

Design, Synthesis, and Bioactivity of Novel Bifunctional Small Molecules for Alzheimer's disease.

Structural Optimization and Biological Evaluation of Substituted Bisphenol A Derivatives As Beta-Amyloid Peptide Aggregation Inhibitors.

Macromolecular and small-molecule modulation of intracellular Aβ42 aggregation and associated toxicity.

Biomimetic Dendrimer–Peptide Conjugates for Early Multi‐Target Therapy of Alzheimer's Disease by Inflammatory Microenvironment Modulation

A Beta-Binding Molecules: Possible Application As Imaging Probes And As Anti-Aggregation Agents

Inhibition of Aβ Aggregation and Tau Phosphorylation with Functionalized Biomimetic Nanoparticles for Synergic Alzheimer’s Disease Therapy

Platinum-coordinated Graphitic Carbon Nitride Nanosheet Used for Targeted Inhibition of Amyloid Β-Peptide Aggregation

Inhibition of Aβ Aggregation and Tau Phosphorylation with Functionalized Biomimetic Nanoparticles for Synergic Alzheimer's Disease Therapy

Design of Multifunctional Agent Based on Basified Serum Albumin for Efficient in Vivo Β-Amyloid Inhibition and Imaging.

Design of Self-Assembled Nanoparticles As a Potent Inhibitor and Fluorescent Probe for Β-Amyloid Fibrillization.